Skip to main content

이정옥 교수

Jeong Ok Lee

서울대학교 내과 · 의학

연구실 소개

이정옥 교수의 연구실은 혈액 및 대사질환, 특히 철결핍과 빈혈의 유병률 및 위험요인을 분석하는 데 초점을 맞추고 있습니다. 특히 성별과 생애주기별로 차이를 보이는 철결핍의 특성과 그 기전을 규명하는 데 기여하고 있으며, 이는 임상적 진단 및 예방 전략 수립에 기여합니다. 또한 유전자 및 세포 기반 연구를 통해 약물 반응성과 질병 메커니즘을 탐색하는 분야로도 확장되고 있습니다.

철결핍빈혈유전적 위험요인임상연구약물반응성

연구 현황

논문 수
249
총 인용 수
3,570
최근 5년 논문
60
주요 분야
의학

연구 성과 추이

표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.

5개년 연도별 논문 게재 수
60총합
2022
2023
2024
2025
2026
5개년 연도별 피인용 수
256총합
20222023202420252026

주요 논문

15
1
논문|인용수 159·2011
Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer
Jeong‐Ok Lee, Tae Min Kim, Se‐Hoon Lee, Dong‐Wan Kim, Soyeon Kim, Yoon‐Kyung Jeon, Doo Hyun Chung, Woo Ho Kim, Young Tae Kim, Seok-Chul Yang, Young Whan Kim, Dae Seog Heo
SJR Q1Journal of Thoracic Oncology
Pulmonary and Respiratory MedicineMedicine
2
논문|인용수 76·2014
Prevalence and Risk Factors for Iron Deficiency Anemia in the Korean Population: Results of the Fifth Korea National Health and Nutrition Examination Survey
Jeong‐Ok Lee, Ju Hyun Lee, Soyeon Ahn, Jin Won Kim, Hyun Chang, Yu Jung Kim, Keun‐Wook Lee, Jee Hyun Kim, Soo‐Mee Bang, Jong Seok Lee
SJR Q2Journal of Korean Medical ScienceOA

This study assessed the prevalence of, and risk factors for, iron deficiency (ID) and iron deficiency anemia (IDA) among participants of the fifth Korean Health and Nutrition Examination Survey, 2010. Of 8,958 participants, 6,758 individuals ≥10 yr had sufficient data for the analysis of anemia and iron status. ID was defined as a transferrin saturation <10% or serum ferritin <15 µg/L. The prevalence of ID and IDA was 2.0% (95% confidence interval [CI], 1.3%-2.6%) and 0.7% (95% CI, 0.3%-1.0%), r

HematologyMedicine
3
논문|인용수 42·2014
Prevalence and Risk Factors for Iron Deficiency Anemia in the Korean Population: Results of the Fifth Korea National Health and Nutrition Examination Survey
이정옥, 안소연, 김진원, 장현, 김유정, 이근욱, 김지현, 방수미, 이종석, 이주현
Journal of Korean Medical Science

This study assessed the prevalence of, and risk factors for, iron deficiency (ID) and iron deficiency anemia (IDA) among participants of the fifth Korean Health and Nutrition Examination Survey, 2010. Of 8,958 participants, 6,758 individuals ≥10 yr had sufficient data for the analysis of anemia and iron status. ID was defined as a transferrin saturation <10% or serum ferritin <15 μg/L. The prevalence of ID and IDA was 2.0% (95% confidence interval [CI], 1.3%-2.6%) and 0.7% (95% CI, 0.3%-1.0%), r

4
논문|인용수 35·2017
Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials
Koung Jin Suh, Ji Yun Lee, Dong‐Yeop Shin, Youngil Koh, Soo‐Mee Bang, Sung‐Soo Yoon, Seonyang Park, Inho Kim, Jeong‐Ok Lee, Jeong‐Ok Lee, Jeong‐Ok Lee
SJR Q2International Journal of Hematology
HematologyMedicine
5
논문|인용수 30·2010
Expression phenotype changes of EBV‐transformed lymphoblastoid cell lines during long‐term subculture and its clinical significance
Jeong‐Ok Lee, H.‐Y. Nam, Sung-Mi Shim, G.‐R. Bae, B. G. Han, Jae Pil Jeon
SJR Q1Cell Proliferation

OBJECTIVES: The EBV-transformed lymphoblastoid cell line (LCL) is a useful resource for population-based human genetic and pharmacogenetic studies. The principal objective here was to assess expression phenotype changes during long-term subculture of LCLs, and its clinical significance. MATERIALS AND METHODS: We searched for genes that were differentially expressed in 17 LCLs at late (p161) passage compared to early passage (p4) using microarray assay, then validated them by real-time RT-PCR ana

OncologyMedicine
6
논문|인용수 28·2009
Metastatic Adrenocortical Carcinoma Treated with Sunitinib: A Case Report
Jeong‐Ok Lee, Jeong-Ok Lee, Keun‐Wook Lee, Chung-Jong Kim, Yu Jung Kim, Hee Eun Lee, Haeryoung Kim, Jee Hyun Kim, Soo‐Mee Bang, Kim Js, Jong Seok Lee, Jong Seok Lee
SJR Q2Japanese Journal of Clinical OncologyOA

Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis. Palliative chemotherapy can be considered in patients with metastatic disease. Although mitotane- or cisplatin-based chemotherapy regimens are widely used, the effects of these agents have been limited. We have experienced a case that showed a partial response with sunitinib after failure of mitotane-based cytotoxic chemotherapy. The clinical benefit from sunitinib persisted 7.5 months in this case. To our knowledge, this i

SurgeryMedicine
7
논문|인용수 27·2008
Risk factors for bacterial pneumonia after cytotoxic chemotherapy in advanced lung cancer patients
Jeong‐Ok Lee, Dae-Young Kim, Joo Han Lim, Myung-Deock Seo, Hyeon Gyu Yi, Yu Jung Kim, Se‐Hoon Lee, Dong-Wan Kim, Seok-Chul Yang, Young Whan Kim, Dae Seog Heo
SJR Q1Lung Cancer
OncologyMedicine
8
논문|인용수 22·2020
Pneumocystis jirovecii pneumonia in diffuse large B‐cell Lymphoma treated with R‐CHOP
Ji Yun Lee, Ji Yun Lee, Min-Su Kang, Koung Jin Suh, Ji‐Won Kim, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Kyoung‐Ho Song, Eu Suk Kim, Hong Bin Kim, Keun‐Wook Lee
SJR Q1Mycoses

BACKGROUND: The aim of this study was to estimate the incidence of and risk factors for Pneumocystis pneumonia (PCP) infection in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). METHODS: The medical records of 739 DLBCL patients who received R-CHOP between May 2004 and January 2019 were retrospectively evaluated. Patients were divided into two groups: those who received primary PCP prophylaxis (prophyl

EpidemiologyMedicine
9
논문|인용수 21·2022
Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy
Shivani Handa, Jeong‐Ok Lee, Andriy Derkach, Richard M. Stone, Alan Saven, Jessica K. Altman, Michael R. Grever, Kanti R. Rai, Madhulika Shukla, Shreya Vemuri, Skye Montoya, Justin Taylor
SJR Q1BloodOA

Vemurafenib, an oral BRAF inhibitor, has demonstrated high response rates in relapsed/refractory (R/R) hairy cell leukemia (HCL). However, little is known about long-term outcomes and response to retreatment. Herein, we report the results of 36 patients with R/R HCL treated with vemurafenib from the United States arm of the phase 2 clinical trial (NCT01711632). The best overall response rate was 86%, including 33% complete response (CR) and 53% partial response (PR). After a median follow-up of

GeneticsMedicine
10
논문|인용수 17·2017
Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy
Se Hyun Kim, Mi Jung Kim, Yu Jung Kim, Hyun Chang, Jin Won Kim, Jeong‐Ok Lee, Keun‐Wook Lee, Jee Hyun Kim, Soo‐Mee Bang, Jong Seok Lee
SJR Q3MedicineOA

Paclitaxel has been shown to have clinical activity in the treatment of small cell lung cancer (SCLC). However, its role as third-line chemotherapy for SCLC after both etoposide- and camptothecin-based regimens has not been clarified.All patients with refractory SCLC who were treated with paclitaxel-based regimen as third-line chemotherapy between 2005 and 2011 in Seoul National University Bundang Hospital were reviewed retrospectively. Forty patients previously treated with both etoposide- and

OncologyMedicine
11
논문|인용수 12·2019
Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement
Jihyun Kwon, Kui‐Jin Kim, Ji Hea Sung, Koung Jin Suh, Ji Yun Lee, Ji Yun Lee, Ji‐Won Kim, Se Hyun Kim, Jeong‐Ok Lee, Jeong‐Ok Lee, Jin Won Kim, Yu Jung Kim
SJR Q1CellsOA

Background: The aim of this study is to elucidate the mechanisms of acquired resistance to pemetrexed in echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer. Methods: We analyzed the sensitivity to pemetrexed and the expression patterns of various proteins after pemetrexed treatment in the cell lines, A549, NCI-H460, NCI-H2228 harboring EML4-ALK variant 3, and NCI-H3122 harboring EML4-ALK variant 1. Pemetrexed-resistant c

Pulmonary and Respiratory MedicineMedicine
12
논문|인용수 11·2010
Clinical Outcomes of Sorafenib Treatment in Patients With Metastatic Hepatocellular Carcinoma Who Had Been Previously Treated With Fluoropyrimidine Plus Platinum-based Chemotherapy
Ji‐Won Kim, Jeong‐Ok Lee, Sae‐Won Han, Do‐Youn Oh, Seock‐Ah Im, Tae‐You Kim, Yung‐Jue Bang
SJR Q3American Journal of Clinical Oncology

Sorafenib had modest efficacy and tolerable toxicity in patients with metastatic HCC who had received fluoropyrimidine plus platinum-based chemotherapy.

HepatologyMedicine
13
논문|인용수 11·2002
학부모의 학교계속구강건강관리사업에 관한 지식수준과 지지정도
이정옥, 문혁수, 김종배, 백대일

Knowledge and attitude of students' parents on school -basedincremental dental care in middle size of urban community

14
논문|인용수 10·2016
Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population
Ja Min Byun, Jeong‐Ok Lee, Beodeul Kang, Ji‐Won Kim, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Keun‐Wook Lee, Soo‐Mee Bang, Jong Seok Lee
SJR Q3Clinical Lymphoma Myeloma & Leukemia
Pathology and Forensic MedicineMedicine
15
논문|인용수 9·2018
Incidence and predictors of venous thromboembolism in medically ill hospitalized elderly cancer patients: a prospective observational study
Jeong‐Ok Lee, Ji Yun Lee, Eun Ju Chun, Sang Il Choi, Jin Won Kim, Se Hyun Kim, Yu Jung Kim, Keun‐Wook Lee, Jee Hyun Kim, Jong Seok Lee, Soo‐Mee Bang
SJR Q1Supportive Care in Cancer
Internal MedicineMedicine

대표 연구 분야

HematologyOncologyGeneticsPathology and Forensic MedicinePulmonary and Respiratory MedicineFood Science

이정옥 교수의 연구를 Nubint에서 더 깊이 살펴보세요

이 연구실의 논문을 앱에서 열어 AI와 함께 읽고, 핵심을 요약하고, 내 글에 인용하세요.